]>
IRCT2016121531427N1 IRCT 2017-02-25 Vice Chancellor for Research and Technology Mashhad University of Medical Sciences The effect of camel milk with Alhagi maurorum Medik on chronic kidney disease Compare the effects of camel milk with Alhagi maurorum Medik. and current treatments on glomerular filtration rate in patients with chronic kidney disease 2017-03-05 anticipated 60 Complete https://irct.ir/trial/24722 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: Randomization will be done with table of random numbers, Randomization description: Random number table. 2 Condition 1: Chronic kidney disease, stage 1. Condition 2: Chronic kidney disease, stage 2. Condition 3: Chronic kidney disease, stage 3. Condition 4: Chronic kidney disease, stage 4. Intervention 1: The intervention group in addition to routine treatment will receive camel milk a daily dose of 400 ml for three months. Intervention 2: The control group will receive the routine Treatments. Yes - There is a plan to make this available What will be shared: Laboratory information When: Six months after printing results To whom: Researchers working in academia and academia Conditions: Researchers working in academia and academia Where to obtain: tavassolyap1@mums.ac.ir How to obtain: 2 months Comments:
public Amirparviz Tavassoli
Faculty of Iranian Traditional Medicine and Complementary, Opposite the Mehran sports hall, East Razi Ave.
Mashhad Iran (Islamic Republic of) 9184643741 +98 51 3855 2189 tavassolyap1@mums.ac.ir Mashhad University of Medical Sciences scientific Sayyid Musa al-Reza Hosseini
Qaem Educational, Research and Treatment Center
Mashhad Iran (Islamic Republic of) 9184643741 +98 51 3855 2189 HoseiniMR@mums.ac.ir Mashhad University of Medical Sciences Iran (Islamic Republic of) patients with chronic kidney disease; aged 15 to 70 years 15 years 70 years Both Patients with chronic kidney disease concomitant uncontrolled diabetes(Hb A1c less than 9 and fasting blood sugar greater than 130) Patients with uncontrolled hypertension(systolic blood pressure of 160 mm Hg and higher and diastolic blood pressure of 100 mm Hg and higher) cancer patients patients with urinary obstruction the fifth stage of chronic kidney disease patients with acute infection and feverish patients who are taking nephrotoxic drugs patients with heart failure liver failure poly cystic kidney pregnancy patients who had kidney transplant drug addicts N18.1 N18.2 N18.3 N18.4 Kidney damage with normal or increased GFR (> 90 mL/min) Kidney damage with mild decreased GFR (60-89 mL/min) Kidney damage with moderately decreased GFR (30-59 mL/min) Kidney damage with severely decreased GFR (15-29 mL/min) Treatment - Other Treatment - Drugs The intervention group in addition to routine treatment will receive camel milk a daily dose of 400 ml for three months. The control group will receive the routine Treatments Glomerular filtration rate. Timepoint: Before the intervention, the end of intervention. Method of measurement: Cockcroft gault Formula, MDRD. Hb. Timepoint: The beginning of the study, the end of the study. Method of measurement: Laboratory blood test. Urinary albumin. Timepoint: The beginning of the study, the end of the study. Method of measurement: Evaluation of urine. 24 hour urine protein level. Timepoint: The beginning of the study, the end of the study. Method of measurement: 24 hour urine evaluation. Serum alkaline phosphatase levels. Timepoint: The beginning of the study, the end of the study. Method of measurement: Laboratory blood test. Serum PTH level. Timepoint: The beginning of the study, the end of the study. Method of measurement: Laboratory blood test. Blood uric acid. Timepoint: Before the intervention, the end of intervention. Method of measurement: Laboratory blood test. Serum calcium. Timepoint: The beginning of the study, the end of the study. Method of measurement: Laboratory blood test. Serum sodium. Timepoint: The beginning of the study, the end of the study. Method of measurement: Laboratory blood test. Serum potassium. Timepoint: The beginning of the study, the end of the study. Method of measurement: Laboratory blood test. Serum CRP levels. Timepoint: The beginning of the study, The end of the study. Method of measurement: Laboratory blood test. Blood pressure. Timepoint: The beginning of the study, the end of the study. Method of measurement: By Sphygmomanometer. FBS. Timepoint: The beginning of the study,Middle of the study, The end of the study. Method of measurement: Laboratory blood test. HbA1C. Timepoint: The beginning of the study, the end of the study. Method of measurement: Laboratory blood test. Lipid profile. Timepoint: The beginning of the study, the end of the study. Method of measurement: Laboratory blood test. Serum creatinine. Timepoint: Before the intervention, the end of intervention. Method of measurement: Evaluation of serum. Vice Chancellor for Research and Technology Mashhad University of Medical Sciences Approved 2016-12-10 Ethics committee of Mashhad University of Medical Sciences Vice Chancellor for Research and Technology Mashhad University of Medical Sciences, Building Qureshi, Daneshgah Ave. Mashhad Razavi Khorasan Iran (Islamic Republic of)